Europe Pharmacovigilance and Drug Safety Software Market Forecast, Regional Share and Growth Opportunity Analysis to 2031
ArisEurope, ICON, Syneos Health, Accenture, IQVIA, Genpact, Cognizant, Paraxel International, Laboratory Corporation of ...
Notice of Extraordinary General Meeting in Ascelia Pharma AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / January ...
Insurers should have to give prior-authorization answers in 20 minutes in Iowa | Opinion
Prior authorization delays are frustrating and, more important, unnecessary, so Iowa law should require fast answers, writes ...
Le Lézard8d
Collibra Strengthens AI Governance Leadership with ISO 42001 Certification, AI Pact Commitment and the Delivery of the EU AI Act Assessment Tool
NEW YORK and BRUSSELS, Jan. 22, 2025 /PRNewswire/ -- Collibra, the Data Intelligence company, announces three major milestones reinforcing its commitment to driving reliable and compliant AI ...
Trump orders all executive agencies to place DEI employees on leave: Updates
Tuesday marks President Donald Trump's first full day in office. Keep up with the USA TODAY Network's coverage of his top ...
Live updates: Trump admin orders all executive agencies to place DEI employees on leave
Tuesday marks Donald Trump's first full day in office. Keep up with the USA TODAY Network's live coverage on his top priorities for Americans.
Vanda Pharmaceuticals Files for New Drug Application for Tradipitant for Motion Sickness Treatment
Vanda Pharmaceuticals Inc. recently made a significant move by filing a new drug application for Tradipitant. The application, targeted at addressing motion sickness, was publicized through a social ...
Yahoo Finance13d
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
January 17, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application ...
Vyluma Announces Acceptance of Drug Application for NVK002 by China’s National Medical Products Administration (NMPA)
With its acceptance by the NMPA, NVK002 is now under regulatory review across three major global markets: the United States, the European Union, and China. This milestone reinforces Vyluma’s vision of ...
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...